Legend Biotech shares tumble as Carvykti outlook overshadows profit
Cancer treatment developer Legend Biotech Corp. (LEGN.US) reported on Tuesday that its third-quarter revenue rose 32% year-on-year to $359.5 million, while its net income reached $51.7 million, reversing a $39.6…
RELATED ARTICLES
-
Legend Bio CEO resigns, shares tumble
- BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
- Legend Biotech names new CEO
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
- CStone’s CS2009 trispecific antibody reinforces three clinical validations at ESMO
-
GDS lifts EBITDA outlook as AI-driven bookings hit record
GDS.US
-
So-Young finds beauty in growing economies of scale
SY.US
